title: [Comparison of efficacy and safety of two different dose of recombinant human thrombopoietin regimens in severe aplastic anemia patients with immunosuppressive therapy].
abstract: OBJECTIVE
  To compare the short-term therapeutic effect of different regimens combining recombinant human thrombopoietin (rhTPO) with immunosuppressive therapy (IST) applied in severe aplastic anemia (SAA).
  
  
  METHODS
  The clinical data of newly diagnosed adult SAA patients treated with first-line IST, including 18 patients with rhTPO daily and 43 patients with rhTPO every other day, was analyzed retrospectively.
  
  
  RESULTS
  There was no significant difference between the basic clinical characteristics of the patients classified in different groups. The therapeutic effect was assessed 3 months and 6 months after IST. The statistical data revealed that the overall responses (OR) were not significantly different in daily group and every other day group (3 months: 50.0% vs 51.2%, P=0.934; 6 months: 77.8% vs 69.8%, P=0.525), while the good hematological response (CR+GPR) in SAA treated with rhTPO daily was significantly higher than that of patients treated with rhTPO every other day at 3 month after IST (38.9% vs 9.3%,P=0.011). RBC transfusion independence were not significantly different between the two groups after 4 weeks as well as 8 weeks treatment(4 weeks: 22.2% vs 18.6%,P=0.736; 8 weeks: 55.6% vs 46.5%,P=0.519), while platelet transfusion independence in rhTPO daily treated group was significantly higher than that in every other day group (88.9% vs 48.8%,P=0.003). In addition, there were no more adverse events observed in rhTPO daily group.
  
  
  CONCLUSIONS
  It's more effective to promote hematopoietic recovery and reduce platelet transfusion dependence when rhTPO was daily used other than used every other day.
authors.affiliation: Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC, Tianjin 300020, China.
authors.forename: K
authors.initials: K
authors.lastname: Zhou
authors.forename: Y
authors.initials: Y
authors.lastname: Li
authors.forename: J P
authors.initials: JP
authors.lastname: Li
authors.forename: H H
authors.initials: HH
authors.lastname: Fan
authors.forename: L
authors.initials: L
authors.lastname: Zhang
authors.forename: L P
authors.initials: LP
authors.lastname: Jing
authors.forename: G X
authors.initials: GX
authors.lastname: Peng
authors.forename: L
authors.initials: L
authors.lastname: Ye
authors.forename: Y
authors.initials: Y
authors.lastname: Li
authors.forename: L
authors.initials: L
authors.lastname: Song
authors.forename: X
authors.initials: X
authors.lastname: Zhao
authors.forename: W R
authors.initials: WR
authors.lastname: Yang
authors.forename: Z J
authors.initials: ZJ
authors.lastname: Wu
authors.forename: F
authors.initials: F
authors.lastname: Chen
authors.forename: F K
authors.initials: FK
authors.lastname: Zhang
mesh_terms: D000328:Adult; D000741:Anemia, Aplastic / Q000188:drug therapy*; D001803:Blood Transfusion; D006801:Humans; D007165:Immunosuppression Therapy; D010976:Platelet Count; D017713:Platelet Transfusion; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000627:therapeutic use; D012189:Retrospective Studies; D013926:Thrombopoietin / Q000008:administration & dosage* / Q000627:therapeutic use
chemical_list: D011994:Recombinant Proteins; D013926:Thrombopoietin